Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amphstar Pharmaceuticals (AMPH)

Amphastar Q3 GAAP EPS falls to $0.37 from $0.78 on $23.1 million litigation charge

Mixed Impact 3 of 5 earnings Written later

Amphastar reported third-quarter 2025 net revenues of $191.8 million, roughly flat from $191.2 million a year earlier. GAAP diluted EPS fell to $0.37 from $0.78, and the company said general and administrative expenses rose mainly because of a $23.1 million litigation provision. Adjusted non-GAAP diluted EPS was $0.93, compared with $0.96 a year earlier.

Key points

  • Net revenues were $191.8 million, up $626 thousand (0%) from $191.2 million in the third quarter of 2024.
  • GAAP net income was $17.4 million, down from $40.4 million; GAAP diluted EPS was $0.37 versus $0.78.
  • Adjusted non-GAAP diluted EPS was $0.93 versus $0.96; the adjustments include a $23.1 million litigation provision.
  • BAQSIMI sales rose 33% to $53.6 million, while glucagon sales fell 49% to $13.6 million.

The filing

CompanyAmphstar Pharmaceuticals (AMPH)
Form8-K, current report
Filed with the SECNov 6, 2025, 4:25 PM ET
Accession number0001297184-25-000062

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.